Table 1.
Characteristics of patients
| Characteristics of patients | Cy TBI | Oral BuCy | IV BuCy | Overall p- value |
|---|---|---|---|---|
| Number of patients | 222 | 354 | 97 | |
| Number of centers | 75 | 68 | 47 | |
| Patient-Related | ||||
| Age, median (range), years | 35 (18- 59) |
34 (18- 59) |
39 (18- 61) |
0.018 |
| 18-30 | 73 (33) | 136 (38) | 28 (29) | 0.167 |
| 31-40 | 80 (36) | 116 (33) | 28 (29) | |
| 41-50 | 47 (21) | 75 (21) | 27 (28) | |
| >50 | 22 (10) | 27 ( 8) | 14 (14) | |
| Sex | 0.293 | |||
| Male | 145 (65) | 211 (60) | 56 (58) | |
| Karnofsky performance score at transplant | 0.142 | |||
| <90% | 19 ( 9) | 21 ( 6) | 11 (11) | |
| >=90% | 193 (87) | 326 (92) | 83 (86) | |
| Missing | 10 ( 5) | 7 (2) | 3 (3) | |
| Disease-Related | ||||
| Time from diagnosis to transplant, median (range), months | 10 (3 - 79) | 9 (2 - 96) | 10 (2 - 149) |
0.813 |
| TKI use pre transplant | <0.001 | |||
| No | 143 (64) | 258 (73) | 32 (33) | |
| Yes | 79 (36) | 96 (27) | 65 (67) | |
| Transplant-Related | ||||
| Donor-recipient sex match | 0.503 | |||
| M-M | 102 (46) | 139 (39) | 37 (38) | |
| F-M | 43 (19) | 72 (20) | 19 (20) | |
| M-F | 44 (20) | 70 (20) | 24 (25) | |
| F-F | 33 (15) | 73 (21) | 17 (18) | |
| Donor Relation | <0.001 | |||
| HLA-identical sibling | 80 (36) | 293 (83) | 65 (67) | |
| Well-matched URD | 142 (64) | 61 (17) | 32 (33) | |
| Donor-recipient CMV serological status | <0.001 | |||
| +/+ | 75 (34) | 74 (21) | 26 (27) | |
| +/− | 56 (25) | 197 (56) | 35 (36) | |
| −/+ | 36 (16) | 26 ( 7) | 13 (13) | |
| −/− | 49 (22) | 45 (13) | 17 (18) | |
| Missing | 6 (3) | 12 ( 3) | 6 (6) | |
| HLA-iden sibling donor age, median (range), years | 37 (13 - 70) |
34 (3 - 65) | 40 (20 - 61) |
<0.001 |
| Unrelated donor age, median (range), years | 35 (19 - 61) |
33 (20 - 46) |
38 (21 - 51) |
0.063 |
| Graft type | <0.001 | |||
| Bone Marrow | 146 (66) | 168 (47) | 49 (51) | |
| Peripheral blood | 76 (34) | 186 (53) | 48 (49) | |
| Conditioning regimen | ||||
| Bu dose, median (range), mg/kg | -- | 16 (10 - 25) |
12 (9-17) | -- |
| Cy/TBI (nonfrac 550-750) | 9 ( 4) | 0 | 0 | |
| Cy/TBI (nonfrac 800-1200) | 4 ( 2) | 0 | 0 | |
| Cy/TBI (frac 900-1170) | 13 ( 6) | 0 | 0 | |
| Cy/TBI (frac 1200-1300) | 123 (55) | 0 | 0 | |
| Cy/TBI (frac 1320-1395) | 40 (18) | 0 | 0 | |
| Cy/TBI (frac 1400-1500) | 33 (15) | 0 | 0 | |
| ATG or alemtuzumab use | 0.004 | |||
| Yes | 41 (18) | 32 (9) | 13 (13) | |
| No | 181 (82) | 322 (91) | 84 (87) | |
| GVHD prophylaxis * | <0.001 | |||
| TAC + MMF +− others | 6 (3) | 1 (<1) | 4 (4) | |
| TAC + MTX +− others (except MMF) | 49 (22) | 23 (6) | 44 (45) | |
| TAC + others (except MTX, MMF) | 6 (3) | 2 (<1) | 0 | |
| TAC alone | 2 (<1) | 0 | 1 (1) | |
| CSA + MMF +− others (except TAC) | 6 (3) | 4 ( 1) | 2 (2) | |
| CSA + MTX +− others (except TAC, MMF) | 140 (63) | 307 (87) | 40 (41) | |
| CSA + others (except TAC, MTX, MMF) | 5 (2) | 3 (<1) | 1 (1) | |
| CSA alone | 6 (3) | 4 (1) | 1 (1) | |
| Other | 0 | 2 (<1) | 3 (3) | |
| Missing | 2 (<1) | 8 (2) | 1 (1) | |
| Growth factors given post transplant | 0.299 | |||
| No | 172 (77) | 253 (71) | 72 (74) | |
| Yes | 49 (22) | 101 (29) | 25 (26) | |
| Missing | 1 (<1) | 0 | 0 | |
| Year of transplant | <0.001 | |||
| 2000 | 81 (36) | 93 (26) | 9 (9) | |
| 2001 | 45 (20) | 44 (12) | 8 (8) | |
| 2002 | 28 (13) | 59 (17) | 5 (5) | |
| 2003 | 15 (7) | 26 (7) | 10 (10) | |
| 2004 | 14 ( 6) | 43 (12) | 28 (29) | |
| 2005 | 21 (9) | 54 (15) | 19 (20) | |
| 2006 | 18 (8) | 35 (10) | 18 (19) | |
| Median follow-up of survivors, range, months | 72 (2-127) | 56 (2- 129) |
59 (3- 119) |
*
Cy indicates Cyclophosphamide; TBI, total body irradiation; Bu, busulfan; ATG, antithymocyte globulin; GvHD, graft versus host disease; TAG, tacrolimus; MMF, mycophenolate mofetil; MTX, methotrexate; GSA, cyclosporine, TKI, tyrosine kinase inhibitor